Recent developments in the treatment of sepsis

Abstract

Despite advances in supportive care, septic shock remains a major cause of morbidity and mortality. With the identification of the systemic inflammatory response as a major component in the pathogenesis of the septic shock syndrome, much of the recent work has focused on modulating this response. This includes antiendotoxin therapies in patients with Gram-negative sepsis, and therapies to modulate the pro-inflammatory mediators produced in response to infection, such as TNF-α, platelet-activating factor and complement. High-flow haemofiltration has the potential advantage of clearing both endotoxin and pro-inflammatory mediators. Antithrombotic strategies have been investigated and have yielded the first major success in the treatment of sepsis with activated protein C. Nitric oxide produces the cardiovascular features of sepsis and investigators have looked at both reducing its production and mopping up the excess. Attempts to reduce apoptosis have been a new focus in the treatment of sepsis. There have also been recent developments in supportive care suggesting a role for vasopressin and replacement corticosteroid therapy.

• antithrombin
• APC
• C1 inhibitor
• caspase
• complement
• corticosteroids
• endotoxin
• G-CSF
• haemofiltration
• HMG
• immunoglobulin
• L-selectin
• MIF
• nitric oxide
• PAF
• PARS
• pentoxifylline
• sepsis
• TFPI
• TNF
• vasopressin